Ultragenyx Pharmaceutical (RARE) Assets Average (2014 - 2026)

Ultragenyx Pharmaceutical (RARE) has 13 years of Assets Average data on file, last reported at $1.4 billion in Q1 2026.

• On a quarterly basis, Assets Average changed 0.46% year-over-year to $1.4 billion in Q1 2026; TTM through Mar 2026 was $1.4 billion, a 0.46% change from a year earlier, with the FY2025 full-year figure at $1.5 billion, up 1.37% from the prior year.
• Assets Average for Q1 2026 stood at $1.4 billion, up from $1.4 billion in the prior quarter.
• Over the last five years, Assets Average for RARE reached as high as $1.6 billion in Q4 2022 and fell as low as $1.2 billion in Q3 2025.
• Historically, Assets Average has averaged $1.4 billion across 5 years, with a median of $1.4 billion in 2025.
• Across the five-year window, Assets Average grew 23.82% in 2024 and retreated 20.91% in 2025, its largest moves.
• Year by year, Assets Average stood at $1.6 billion in 2022, then dropped by 13.74% to $1.4 billion in 2023, then advanced by 11.44% to $1.5 billion in 2024, then retreated by 10.49% to $1.4 billion in 2025, then gained by 3.88% to $1.4 billion in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $1.4 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.2 billion in Q3 2025.